A Pilot Study to Evaluate Patient Tolerance and Nursing Ease-of-Use of a Novel Hearing Protection Device (NEATCAP)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT02744066 |
|
Recruitment Status :
Completed
First Posted : April 20, 2016
Results First Posted : November 29, 2018
Last Update Posted : November 29, 2018
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Hearing Impairment | Device: NEATCAP | Not Applicable |
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 55 participants |
| Allocation: | N/A |
| Intervention Model: | Single Group Assignment |
| Masking: | None (Open Label) |
| Primary Purpose: | Other |
| Official Title: | A Pilot Study to Evaluate Patient Tolerance and Nursing Ease-of-Use of a Novel Hearing Protection Device to Reduce Exposure to Excessive Noise Among Patients Undergoing Neonatal Intensive Care |
| Actual Study Start Date : | January 31, 2017 |
| Actual Primary Completion Date : | October 5, 2017 |
| Actual Study Completion Date : | October 5, 2017 |
| Arm | Intervention/treatment |
|---|---|
|
Neonates
Neonates admitted to the NICU will be fitted for NEATCAP, non-invasive novel hearing protection device.
|
Device: NEATCAP
Neonates will be sized and fitted to wear the non-invasive novel hearing protection device over a set period of time in the NICU. Vitals will be monitored. |
- Number of Participants With Skin Erythema After Device Application [ Time Frame: Skin erythema was evaluated at the time of device removal after 1 hour of application in phase #1 and after 3 daily 8 hour periods of application in phase #2. ]Skin will be assessed for adverse effects such as any device-related adverse events, including evidence of skin redness, rash and/or bruising or discomfort at the site of device application. Skin erythema was described as none, mild, moderate or severe as evaluated by the NICU nursing staff.
- Number of Participants With Specific Responses to the Ease of Use Questionnaire for NICU Staff. [ Time Frame: After 1 hour in phase #1 / After 3 x 8 hours in phase #2 ]A >80% positive response to a multi-question Ease-of-Use Questionnaire completed by the participating NICU staff. Ease-of-Use Questionnaire constructed on a 5 point Likert Scale: 1 = Strongly Disagree, 2 = Disagree, 3 = Neutral, 4 = Agree, 5 = Strongly Agree that the device was easy-to-use. Phase #1 consists of 25 data points. Phase #2 consists of 25 data points. Evaluations were obtained after device removal in both phases.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | up to 2 Weeks (Child) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Neonate admitted to the Neonatal Intensive Care Unit
- Age greater than 12 hours and less than 2 weeks
- Informed consent from the parent(s)
Exclusion Criteria:
- Significant cranial trauma noted on admission
- Congenital anomalies of the head and/or neck
- Hemodynamic instability requiring pharmacologic intervention
- Recommendation by the attending neonatologist not to enroll the patient
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02744066
| United States, Pennsylvania | |
| Magee Womens, UPMC Hamot | |
| Erie, Pennsylvania, United States, 15607 | |
| Principal Investigator: | Michael J Balsan, MD | Principal Investigator |
Documents provided by Michael Balsan, MD, University of Pittsburgh:
| Responsible Party: | Michael Balsan, MD, Associate Professor of Pediatrics, University of Pittsburgh |
| ClinicalTrials.gov Identifier: | NCT02744066 |
| Other Study ID Numbers: |
PRO16010220 |
| First Posted: | April 20, 2016 Key Record Dates |
| Results First Posted: | November 29, 2018 |
| Last Update Posted: | November 29, 2018 |
| Last Verified: | November 2018 |
| Individual Participant Data (IPD) Sharing Statement: | |
| Plan to Share IPD: | Undecided |
| Studies a U.S. FDA-regulated Drug Product: | No |
| Studies a U.S. FDA-regulated Device Product: | Yes |
| Device Product Not Approved or Cleared by U.S. FDA: | Yes |
| Product Manufactured in and Exported from the U.S.: | No |
|
Hearing Loss Deafness Hearing Disorders Ear Diseases |
Otorhinolaryngologic Diseases Sensation Disorders Neurologic Manifestations Nervous System Diseases |

